The total operating income stood at Rs 256.78 crore for the three months ended June, 2013, as against Rs 357.23 crore for the same period of last year, a drop of 28%.
The company has also informed that it is expecting the transaction of sales of its Penicillin and Penem Active Pharmaceutical Ingredient (API) business and the API facility in Maharashtra to Hospira Healthcare India Private Limited, to be completed before September 30, 2013. The company has earlier informed BSE that the deal agreement has been extended to the end of June 30, 2013.
In its filing of quarterly results today, the company said, "The Company has entered into a Business Transfer Agreement (BTA) dated August 29, 2012 with Hospira Healthcare India Private Limited for the sale and transfer of Orchid’s Penicillin and Penem API business and the API facility located in Aurangabad (Maharashtra) together with an associated Process R&D infrastructure located in Chennai. The transaction is expected to be completed before September 30, 2013."
It may be noted that the company earlier said that it has received all the no objection certificates (NOCs) from the lenders to complete its $200 million deal with the Indian subsidiary of US-based Hospira Inc.
However, the company later went into Corporate Debt Restructuring (CDR) and considering the transaction also part of the CDR discusions, the process would take a little more time, said Ch Ram, head - corporate communications & investor relations, OCPL.
The company expects that once the CDR process is completed there would be an ease in flow of working capital, which would help the company in returning to growth, he added.
The company has extended its financial year (FY 2012-13) by six months to September 30, 2013.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)